Immunohistochemical expression of programmed cell death ligand-1 in non-small cell lung cancer (CROSBI ID 639967)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Pupić-Bakrač, Petra ; Hanžič, Nina ; Matušan- Ilijaš, Koviljka ; Štemberger, Christophe ; Bulat-Kardum, Ljiljana ; Ivančić, Aldo ; Lučin, Ksenija
engleski
Immunohistochemical expression of programmed cell death ligand-1 in non-small cell lung cancer
Background: Programmed cell death ligand-1 (PD- L1) is a transmembrane protein expressed on different non-tumor as well as on tumor cells, serving them to evade detection and elimination by immune system. Lung cancer is the most common cancer in the world and non-small cell lung cancer (NSCLC) represents approximately 80% to 85% of all lung cancers. In the era of new molecular targeted therapies there is a constant need for the investigation of molecular substrate of cancer progression. Aim: To analyze the PDL-1 expression in NSCLC tumor cells (TC) and immune stromal cells (IC) and to compare it to usual clinicopathological parameters. Materials and Methods: Expression of PDL-1 was analyzed immunohistochemically in 110 surgically resected NSCLC tissue microarray samples, using Ventana ready-to-use PD-L1 (SP263) primary antibody. The histological score (H-score) was calculated by multiplying percentage and intensity of staining separately on TC and IC, and was compared to clinicopathological parameters. Results: The expression of PDL-1 was seen in TC as well as in different types of IC as membranous and cytoplasmic staining of different intensity. The median TC H-score was 8.12 (range 0-300), IC H-score was 14.04 (range 0-60) and they showed a significant correlation (p=0.002, rp=0.286). There was no significant difference in PDL-1 expression between different NSCLC histological types. Statistical analysis showed the association between higher level of TC and IC PDL-1 expression and higher histological grade (p=0.002 and p<0.001, respectively), higher pathological stage (p=0.011 and p=0.017, respectively), and advanced clinical stage (p=0.046 and p=0.027, respectively). Also, the level of TC PDL-1 expression correlated with the proliferative activity of tumor cells (p=0.022, rp=0.217), while higher level of IC PDL-1 expression showed the association with pleural infiltration (p=0.026). Conclusion: Our results indicate that PDL-1 may be involved in NSCLC progression, confirming its role as a target for PD-L1 inhibitors that showed benefits in clinical trials.
Immunohistochemistry ; Lung carcinoma ; non-small cell ; Programmed cell death ligand-1 ; Progression
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
2016.
nije evidentirano
Podaci o matičnoj publikaciji
Podaci o skupu
Global Students' Conference of Biomedical Sciences in Belgrade
predavanje
20.10.2016-23.10.2016
Beograd, Srbija